

Formulation and Evaluation of Oro-Dispersible Tablets of Tridax Procumbens Herbal Drug

B Swathy*

Department of Pharmceutical Sciences, Palamuru University, India

ABSTRACT

The novel drug delivery technology is applied in herbal medicine; it may help in increasing the efficacy and reducing the side effects of various herbal compounds and herbs. This is the basic idea behind incorporating novel method such as nanoparticles, micro emulsions, matrix systems, solid dispersions, liposomes, solid lipid nanoparticles etc., to drug delivery of herbal medicines. Thus it is important to integrate novel drug delivery system and Indian ayurvedic medicines to combat more serious diseases. For a long time, herbal medicines were not considered for development as novel formulations owing to lack of scientific justification and processing difficulties, such as standardization, extraction and identification of individual drug components in complex poly herbal systems. I have prepared the Tridax oro-dispersible tablets for wound healing by using super disintegrants.

Keywords: Herbal tridax; Wound healing; Efficacy; Oro dispersible tablets

INTRODUCTION

Herbal drugs are becoming more popular in the modern world not only for their use but also for research because of their application to cure variety of diseases with less toxic effects and better therapeutic effects, widespread availability and lower cost. There are three main reasons for the popularity of herbal medicines:

(1) There is a growing concern and doubts over the reliance and safety of modern drugs and surgery.

(2) Many modern medicines are failing to treat the most common health conditions effectively. On the other side, many natural products and procedures are proving better than drugs or surgery without the side effects [1].

(3) Also there are increasing evidences which suggest that many current drug therapies simply suppress symptoms and ignore the underlying disease causes. In contrast, natural products appear to address the cause of many diseases and yield superior clinical results [2].

Our country has a vast knowledge base of Ayurveda whose potential is only being realized in the recent years. Unfortunately, most physicians and patients are not aware that these natural alternatives exist. However, the drug delivery system used for administering the herbal medicine to the patient is traditional and out of date, resulting in reduced efficacy and acceptance of the drug. Novel drug delivery system is a novel approach to drug delivery that addresses the limitations of the traditional drug delivery systems. Drug delivery system is the method by which an optimum amount of the concerned drug is administered to the patient in such a way that it reaches exactly the 'site of action' and starts working then and there. Novel drug delivery system attempts to eliminate all the disadvantages associated with conventional drug delivery systems. There are various approaches by which novel drug delivery can be achieved [3,4]. Modern medicine cures a particular disease by targeting exactly the affected zone inside a patient's body and transporting the drug to that area.

The method by which a drug is delivered can have a significant effect on its efficacy. Some drugs have an optimum concentration range within which maximum benefit is derived, and concentrations above or below this range can be toxic or produce no therapeutic benefit at all. On the other hand, the very slow progress in the efficacy of the treatment of severe diseases has suggested a growing need for a multidisciplinary approach to the delivery of therapeutics to targets in tissues. From this, new ideas on controlling the pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity, bio-recognition and efficacy of drugs were generated. These new strategies, often called drug delivery systems (DDS), are based on interdisciplinary approaches that combine polymer science, pharmaceutics, bio-conjugate chemistry and molecular biology [5-8].

METHODS

Preparation

Tridax Procumbens leaves were collected in Palamuru University campus and authenticated by department of botany, authenticated leaves were separated, washed and dried under shade.

Tridax procumbens belongs to family Asteraceae, and commonly

Correspondence to: B Swathy, Department of Pharmceutical Sciences, Palamuru University, India, E-mail: Swathybekkeri24319@gmail.com

Received: 02-Jan-2023, Manuscript No. EOED-23-12194 Editor assigned: 04-Jan-2023, PreQC No.EOED-23-12194; (PQ); Reviewed: 18-Jan-2023, QC No.EOED-23-12194 Revised: 25-Jan-2023, Manuscript No. EOED-23-12194 (R); Published: 02-Feb-2023, DOI: 10.35248/ 2329-6631.23.12.187

Citation: B Swathy (2023) Formulation and Evaluation of Oro-Dispersible Tablets of Tridax Procumbens Herbal Drug. J Develop Drugs 12:18 Copyright: © 2023 B Swathy. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

known as Gaddi chamanthi (in telugu), Vettukaaya thalai (in tamil).

Tridax procumbens leaves have vast benefits like wound healing, antidiabetic, antibacterial, antiplasmodial, antihepatotoxic, antioxidant, anti-microbial, immune modulatory and anti-cancer.

The plant was collected from surrounding area of Palamuru University and authenticated by Department of Botany Palamuru University.

Based on literature and traditional knowledge the leaves were selected for wound healing study

Extraction

The extracts of Tridax using a soxhlet extractor from Juice of fresh leaves, dried leaves powder, air dried whole plant is pulverized and extracts are prepared for 72 hours and the yield found to be 6% W/V at room temperature. Standard solutions were prepared in methanol for alkaloids and tannins and methylene chloride for phytosterols.

Extraction was carried out using Ethanolic Water mixture in the ratio of 7:3. To extract all the components by percolation for 48 hrs. The Extract was dried at 40°C and stored in a desiccators. It is used for phyto-chemical screening and standardization (Table 1) (Figure 1).

 Table 1: Standard calibration data.

S.no	Concentration (µg/ml)	Mean absorbance 469 nm		
1.	0	0		
2.	10	0.603		
3.	20	1.202		
4.	30	1.813		
5.	40	2.36		
6.	50	2.903		
7.	60	3.4		
8.	70	3.884		



Figure 1: Preparation of standard calibration curve

The extracts are subjected to phyto-chemical screening using following standard procedures for determining chemical constituents.

- Test for Alkaloids
- Test for Tannins
- Test for Phenol
- Test for Falvonoids

- OPEN OACCESS Freely available online
- Test for Saponins

Table 3: Compatibility studies

The extract is tested for organoleptic studies and physicochemical analysis like moisture content, loss on drying, ash value, acid insoluble value and water soluble value (Table 2).

 Table 2: Phytochemical analysis of the extract.

S.no	Parameters	Observation
1.	Colour	Dark green
2.	Odour	Intense
3.	Taste	Bitter
4.	Moisture content	0.42
5.	Loss on drying	9.5
6.	Ash value	11.02%
7.	Acid insoluble value	2.0
8.	Water soluble value	4.5

Compatibility studies of drug and formulation components

• The compatibility of drug and polymers under experimental conditions is important prerequisite before formulation.

It is therefore necessary to confirm that the drug does not react with the polymers and excipients under experimental conditions and not affecting the shelf life of product or any other unwanted effects on the formulation.

- The physical mixture of drug and polymers was used for compatibility study.
- Mixtures of extract and excipients were kept in sealed vials and observed for any change in physical properties (Table 3).

Sample	Room temp	40°C in oven	30°C ± 2°C/ 65% ± 5%	40°C ± 2°C/ 75% ± 5%	
Extract +Lactose	No Change	No Change	No Change	No Change	
Extract +Man- nitol	No Change	No Change	No Change	No Change	
Extract +PVP K 30	No Change	No Change	No Change	No Change	
Extract +Starch	No Change	No Change	No Change	No Change	
Extract +SSG	No Change	No Change	No Change	No Change	
Crosspovidone	No Change	No Change	No Change	No Change	
Extract+ Crosscar- mellose sodium	No Change	No Change	No Change	No Change	
Extract +Magne- sium stearate	No Change	No Change	No Change	No Change	
Extract +Sod. Sacharine	No Change	No Change	No Change	No Change	
Extract +Citric acid	No Change	No Change	No Change	No Change	

Formulation and evaluation of oro-dispersible tablets of herbal drug

- Oro-dispersible tablets are defined as uncoated tablets intended to be placed in the mouth where they disperse readily within 3 min before swallowing.
- Oro-dispersible tablets are also called as orally disintegrating tablets, mouth-dissolving tablets, rapid-dissolving tablets, fast disintegrating tablets, fast dissolving tablets.
- Like all other solid dosage forms, they are also evaluated for hardness, friability, wetting time, moisture uptake,

OPEN OACCESS Freely available online

disintegration test, and dissolution test.

- Formulation of ODT is done by using super disintegrants, binders, taste enhancers, glidants, diluents, anti-oxidants.
- Lactose, polyvinylpyrollidinek 30, sodium starch glycolate,
- Crosspovidone, crascarmellosesodium, mannitol, magnesium stearate, starch, sodium saccharin, citric acid are used in formulating ODT.
- ODTs are formulated by using direct compression method.

Table 4: Formulation chart for Oro-Dispersible Tablets

• The accurately weighed materials were mixed with required quantities of superdisintegrants, lubricant and blended for 5 minutes in polybag to form a homogenous powder mix and pre formulation studies have been performed for this blends and compressed using 6 mm round concave punch set on an instrumented 16 station rotary tablet press (Cadmach model CMD4, Ahmedabad, India) [9-15] (Tables 4-7).

RESULTS

Post compression evaluation parameters (Tables 8 and 9).

	Formulations							
Ingredients —	F1	F2	F3	F4	F5	F6	F7	F8
Extract	30%	30%	30%	30%	30%	30%	30%	30%
Lactose	30%	30%	30%	30%	30%	30%	30%	30%
Mannitol	25.8	20.8	32.8	31.8	30.8	32.8	31.8	30.8
PVP K 30	2%	2%	2%	2%	2%	2%	2%	2%
Starch	10%	15%	-	-	-	-	-	-
SSG	-	-	3	4	5	-	-	-
Crosspovidone	-	-	-	-	-	3	4	5
Crosscarmel- lose sodium	-		-				-	-
Magnesium stearate	1%	1%	1%	1%	1%	1%	1%	1%
Sod.Sacharine	1%	1%	1%	1%	1%	1%	1%	1%
Citric acid	0.20%	0.20%	0.20%	0.20%	0.20%	0.20%	0.20%	0.20%

Table 5: Formulation chart for Oro-Dispersible Tablets

T 1	Formulations								
Ingredients	F9	F10	F11	F12	F13	F14	F15	F16	
Extract	30%	30%	30%	30%	30%	30%	30%	30%	
Lactose	30%	30%	30%	30%	30%	30%	30%	30%	
Mannitol	32.8	31.8	30.8	32.8	31.8	30.8	31.8	31.8	
PVP K 30	2%	2%	2%	2%	2%	2%	2%	2%	
Starch	-	-	-	-	-	-	-	-	
SSG	-	-	-	-	-	-	2%	-	
Crosspovidone	-	-	-	~	-	-	2%	2%	
Crosscarmellose	3	4	5	-	-	-	-	2%	
Magnesium stearate	1%	1%	1%	1%	1%	1%	1%	1%	
Sod.Sacharine	1%	1%	1%	1%	1%	1%	1%	1%	
Citric acid	0.20%	0.20%	0.20%	0.20%	0.20%	0.20%	0.20%	0.20%	

Table 6: Pre-Formulation studies for powdered drug blend

D –	Formulations							
Parameter	F1	F2	F3	F4	F5	F6	F7	F8
Angle of repose	32 ± 1.2 %	33 ± 1.4 %	31 ± 3.2 %	32 ± 2.1%	32 ± 3.3 %	32 ± 1.4 %	33 ± 1.0 %	30 ± 1.2 %
Tapped Density (g/cm3)Vf	0.552	0.544	0.435	0.437	0.44	0.437	0.439	0.441
Bulk Density (g/cm3) V0	0.621	0.618	0.532	0.541	0.542	0.539	0.542	0.551
Cars index 100 (vo-vf/ vo)	11.1	11.9	18.2	18.8	18.8	18.9	19	19.9
Hausners ratio	1.125	1.136	1.222	1.237	1.231	1.233	1.234	1.249

Table 7: Pre-formulation studies for powdered drug blend

Parameter -	Formulations							
	F9	F10	F11	F12	F13	F14	F15	F16
Angle of repose	30 ± 1.2 %	31 ± 1.2 %	29 ± 1.2 %	30 ± 1.2 %	29 ± 1.2 %	31 ± 1.4 %	30 ± 0.5 %	29 ± 1.7 %
Tapped Density	0.438	0.439	0.441	0.431	0.437	0.438	0.439	0.441
Bulk Density	0.536	0.53	0.544	0.561	0.549	0.531	0.531	0.537
Cars index	18.2	17.1	18.9	23.1	20.4	17.5	17.3	17.8
Hausners ratio	1.223	1.207	1.233	1.301	1.256	1.212	1.209	1.217

Table 8: Post compression evaluation parameter

D	Formulations							
Parameters	F1	F2	F3	F4	F5	F6	F7	F8
Weight varia- tion	250 ± 1.1	250 ± 0.8	250 ± 1.3	250 ± 0.7	250 ± 2.0	250 ± 0.6	250 ± 0.7	250 ± 1.0
Hardness	3.2 ± 0.22	3.1 ± 0.42	3.0 ± 0.85	3.2 ± 0.32	3.3 ± 0.01	3.2 ± 0.64	3.1 ± 0.21	3.2 ± 0.42
Friability	0.82	0.92	0.86 ±	0.82	0.86	0.88	0.75	0.81
Wetting time (Sec)	39 ± 0.8	37 ± 18	23 ± 1.0	22 ± 0.7	21 ± 0.8	22 ± 0.8	22 ± 1.8	22 ± 2.8
Absorption ratio (%)	92.07	97.06	98.05	97.06	97.01	98.09	96.03	97.45
Disintegration time (Sec)	258 ± 1.3	209 ± 0.8	30 ± 0.12	26 ± 0.18	25 ± 0.7	31 ± 0.9	26 ± 0.18	25 ± 0.6

Table 9: Post compression evaluation parameter

D	Formulations							
Parameters	F9	F10	F11	F12	F13	F14	F15	F16
Weight varia- tion	250 ± 0.5	250 ± 0.7	250 ± 0.6	250 ± 0.23	250 ± 0.80	250 ± 0.32	250 ± 0.14	250 ± 0.53
Hardness	3.3 ± 0.31	3.2 ± 0.91	3.2 ± 0.01	3.0 ± 0.21	3.2 ± 0.44	3.2 ± 0.32	3.2 ± 0.61	3.3 ± 0.46
Friability	0.82	0.83	0.84	0.86	0.88	0.89	0.80	0.81
Wetting time (Sec)	22 ± 3.1	22 ± 0.5	24 ± 0.8	23 ± 0.7	22 ± 0.9	28 ± 0.8	21 ± 0.8	21 ± 0.1
Absorption ratio (%)	96.35	98.06	97.97	94.28	96.19	97.36	98.22	98.76
Disintegration time (Sec)	25 ± 0.8	32 ± 1.3	29 ± 2.8	25 ± 2.2	33 ± 2.9	27 ± 0.6	25 ± 2.1	22 ± 1.3

DISCUSSION

According to the evaluation parameters the formulation F16 was selected as optimized as the superdisintegrants crosspovidone and crasscarmellose sodium has shown a good and fast disintegration.

CONCLUSION

In short, in view of the characteristics of pulmonary interstitial inflammation and fibrosis in patients with COVID-19 during recovery period, this study plans to establish an effective treatment program for pulmonary fibrosis/dysfunction in COVID-19 to promote the rehabilitation of patients. The study results would not only provide new methods for the treatment of pulmonary fibrosis due to COVID-19 and information for further understanding the natural history of COVID-19, but provide a potential strategy for treating pulmonary fibrosis caused by other etiologies.

ACKNOWLEDGMENTS

None

CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest.

REFERENCES

- 1. Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med. 2001; 16(135):594-600.
- 2. Herbal and Traditional Medicine. 2nd International Conference. Benefits of Herbal Medicine. 2019 MENA Plaza Hotel
- 3. Souravroy. Why is a novel drug delivery system important for herbal or ayurvedic medicines.
- Musthaba SM, Baboota S, Ahmed S, Ahuja A, Ali J. Status of novel drug delivery technology for phytotherapeutics. Expert Opin Drug Deliv. 2009;6 :625–637.
- Charman WN, Chan HK, Finnin BC, Charman SA. Drug delivery: A key factor in realising the full therapeutic potential of drugs. Drug Dev Res. 1999; 46: 316–327.
- 6. Dhiman A., Nanda A, Ahmad S., "Novel Herbal Drug Delivery System (NHDDS): the need of Hour". IPCBEE 2012; 49: 171-175.
- 7. Kumar K, AK Rai. Miraculous therapeutic effects of herbal drugs using novel drug delivery systems. IRJP. 2012; 3(2): 27-30.
- 8. Bhokare SG, Dongaonkar CC, Lahane SV. Herbal novel drug delivery: A review. World J Pharm Pharma Sci. 2016; 5(8).

- 9. Atram Seema. Recent development of herbal formulation: A novel drug delivery system. Int. Ayurvedic Med J. 2014; 2(6): 953-958.
- Khobragde D, Arun K, Ravalika K, Gupta R, Vasu Kumar P. Oro-dispersible tablets of ayurvedic powder for improving taste, compliance, ease and accuracy of administration. Int. J. Adv. Sci. Res. 2016; 2(06): 131-133.
- 11. Panchal DM, Tiwari A, Srivastava P. A review on orodispersible tablets: A novel formulation for oral drug delivery system and its future prospective. Indo American J Pharm Res.2013;3(2):4149.4168.
- 12. Aslam A, Samee F, Zaman M, Rahman A. formulation and assessment of semi-solid carrier incorporated with herbal extract of lawsonia

inermis. Acta Poloniae Pharmaceutica ñ Drug Res. 2017;74 (2): 497-504.

- Shaik SS, Rao KS, Swati S, Vani T. Formulation and evaluation of herbal fast dissolving buccal film containing curcumin. World J Pharm Pharma Sci. 2018;7(4),:1617-1635.
- Bhupinder B, Sarita J, Kaur M, Singh H. Orally fast dissolving films: innovations in formulation and technology. Int J Pharml Sci Rev Res. 2011; 9(2):51-57.
- 15. Kusum V, Devi V, Jain N, Valli KS. Importance of novel drug delivery systems in herbal medicines. Pharmacogn Rev. 2010; 4(7): 27–31.